Table 4 Atrial fibrillation registry studies worldwide
From: Rationale and design of the Chinese Atrial Fibrillation Registry Study
Studies | Participating centers | Timeline | Follow-up | Sample size | Main purpose |
|---|---|---|---|---|---|
RHYTHM-AF [18] | 10 countries, 175 centers, mostly European countries | May 2010 ~June 2011 | 60 days | 3940 | To describe treatment patterns and short term outcomes related to cardioversion. |
GARFIELD [19] | 50 countries in Europe, Asia-Pacific, Central/South America, and Canada | Started in December 2009, with a planned recruitment period of 4 years | 2-year | 55,000 | To evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. |
GLORIA-AF [20] | Nearly 50 countries in Asia, Europe, North America, Latin America and Africa/Middle East | Phase I: May 2011- January 2013. | Phase II: 2 years | 56,000 | To investigate patient characteristics influencing choice of antithrombotic treatment and to collect data on outcomes of antithrombotic therapy |
Phase II: November 2011 | Phase III: 3 years | ||||
Phase III: early 2014 | |||||
J-RHYTHM [21] | 158 institutions in Japan | January to July 2009 | 2-year | 7937 | To determine the appropriate INR for Japanese AF patients |
PINNACLE-AF [22] | In the United states | October 2011 | - | >300000 | Quality improvement |
The Atrial Fibrillation Ablation Pilot Study [23] | 72 centers in 10 European countries | October 2010 | 1 year | 1410 | to describe the clinical epidemiology and treatment of patients undergoing AF ablation |
ORBIT-AF [24] | 200 US outpatient practices | June 2010 to August 2011. | ≥2 years | 10097 | To characterize treatment and outcomes of patients with AF |